Last reviewed · How we verify
NCT06645912
Effect of High Protein ONS on Older Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy
NA trial testing oral nutritional supplement in Locally Advanced Gastric Adenocarcinoma in 46 participants. Completed in 23 February 2024.
1 February 2024
Quick facts
| Lead sponsor | Erzincan Binali Yildirim University Mengucek Gazi Training and Research Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 46 |
| Start date | 1 February 2023 |
| Primary completion | 1 February 2024 |
| Estimated completion | 23 February 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- oral nutritional supplement
Conditions studied
- Locally Advanced Gastric Adenocarcinoma — all drugs for Locally Advanced Gastric Adenocarcinoma →
Sponsor
Erzincan Binali Yildirim University Mengucek Gazi Training and Research Hospital
Who can join
65 and older, any sex, with Locally Advanced Gastric Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This interventional prospective randomized controlled study was conducted to compare the effects of high-protein oral nutritional supplement (ONS) and medical nutritional therapy to medical nutrition therapy alone on nutritional status, quality of life, and physical function capacity after neoadjuvant chemotherapy in patients aged 65 and over with newly diagnosed locally advanced gastric cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effects of high-protein nutritional supplementation on nutritional status, physical function, and quality of life in older gastric cancer patients receiving neoadjuvant chemotherapy: a randomized trial.
Doğan Akagündüz D, Türker PF, Akagündüz B. · · 2025 · PMID 40782206 · DOI 10.1007/s00520-025-09822-x
Verify or expand the search:
- PubMed search for NCT06645912
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Locally Advanced Gastric Adenocarcinoma
Currently open trials in the same condition.
- NCT06250036 — Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer · Phase 2 · recruiting
- NCT05813015 — Study of Comparing of With and Without Sequential Therapy of S-1 · Phase 3 · recruiting
- NCT05269381 — Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT04007744 — Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors · Phase 1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06645912 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Erzincan Binali Yildirim University Mengucek Gazi Training and Research Hospital
- Last refreshed: 18 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06645912.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing